PLEXBIO CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.5 TWD | +0.81% |
|
+0.40% | -11.35% |
| Apr. 25 | PlexBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | PlexBio Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 191M 5.91M | Sales 2023 | 167M 5.17M | Capitalization | 1.46B 45.16M |
|---|---|---|---|---|---|
| Net income 2022 | -53M -1.64M | Net income 2023 | -58M -1.79M | EV / Sales 2022 | 4.06 x |
| Net cash position 2022 | 473M 14.63M | Net cash position 2023 | 417M 12.89M | EV / Sales 2023 | 6.25 x |
| P/E ratio 2022 |
-23.5
x | P/E ratio 2023 |
-25.2
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 14.47% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.81% | ||
| 1 week | +0.40% | ||
| Current month | +0.40% | ||
| 1 month | +4.17% | ||
| 3 months | -9.09% | ||
| 6 months | -10.39% | ||
| Current year | -11.35% |
1 week
12.25
13.05
1 month
11.2013.05
Current year
11.2014.65
1 year
11.2019.45
3 years
11.2055.00
5 years
11.20115.00
10 years
11.20115.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ting Tsao
CEO | Chief Executive Officer | - | 09-12-16 |
Chia Hung Hung
DFI | Director of Finance/CFO | - | 18-05-24 |
Li Pi Yeh
DFI | Director of Finance/CFO | - | 17-05-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Te Feng Tsao
BRD | Director/Board Member | 78 | 16-06-29 |
Ting Tsao
CEO | Chief Executive Officer | - | 09-12-16 |
Sonny Wang
BRD | Director/Board Member | - | 21-08-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 12.5 | +0.81% | 166,401 |
| 24-05-03 | 12.4 | +0.40% | 148,626 |
| 24-05-02 | 12.35 | -0.80% | 70,004 |
| 24-04-30 | 12.45 | 0.00% | 71,002 |
End-of-day quote Taipei Exchange, May 05, 2024
More quotes
PlexBio Co., Ltd. is a Taiwan-based company mainly engaging in provision of diversified testing equipment platform and multiple testing reagent. The Company's main products include medical testing equipment such as diversified in-vitro diagnostic (IVD) medical devices, reagents and others. The Company distributes its products within domestic markets and to overseas markets, including Taiwan, mainland China, American and other areas.
| 1st Jan change | Capi. | |
|---|---|---|
| -11.35% | 40.08M | |
| -3.82% | 184B | |
| -0.50% | 109B | |
| -2.27% | 68.37B | |
| +4.54% | 51.56B | |
| +9.49% | 44.69B | |
| +4.37% | 41.49B | |
| +1.91% | 26.75B | |
| +3.88% | 26.7B | |
| +15.38% | 25.68B |
- Stock Market
- Equities
- 6572 Stock